Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (formerly Microbia) is dedicated to creating, developing, and commercializing innovative human medicines, and has clinical stage programs in GI disorders and dyslipidemia. The Company discovered, developed and is commercializing a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Ironwood is also developing a rich pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract.

Company Growth (employees)
Type
Public
HQ
Cambridge, US
Size (employees)
674 (est)
Ironwood Pharmaceuticals is headquartered in Cambridge, US

Key People at Ironwood Pharmaceuticals

Peter Hecht

Peter Hecht

Co-Founder
Brian Cali

Brian Cali

Co-Founder and Vice President of Program Management

Ironwood Pharmaceuticals Office Locations

Ironwood Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
301 Binney St

Ironwood Pharmaceuticals Data and Metrics

Ironwood Pharmaceuticals Financial Metrics

Ironwood Pharmaceuticals's revenue was reported to be $52.2 m in Q1, 2017
USD

Revenue (Q1, 2017)

52.2 m

Net income (Q1, 2017)

(52.5 m)

EBIT (Q1, 2017)

(39.7 m)

Market capitalization (17-Aug-2017)

2.2 b

Cash (31-Mar-2017)

133.3 m
Ironwood Pharmaceuticals's current market capitalization is $2.2 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

22.9 m76.4 m149.6 m274 m

Revenue growth, %

234%96%83%

Gross profit

15.7 m50.9 m149.5 m

Gross profit Margin, %

69%67%100%

R&D expense

139.5 m

General and administrative expense

173.3 m

Operating expense total

267.7 m220.2 m251.6 m312.8 m

EBIT

(252 m)(169.4 m)(102.1 m)(51.9 m)

EBIT margin, %

(1101%)(222%)(68%)(19%)

Interest expense

(39.2 m)

Net Income

(272.8 m)(189.6 m)(142.7 m)(81.7 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

52.2 m

Cost of goods sold

10.5 m12 k8.2 m12 k12 k

R&D expense

22.1 m25.1 m26.6 m28.6 m25.8 m31.8 m31.7 m37.5 m33.7 m

General and administrative expense

29.3 m28.5 m30.3 m33 m30.4 m36.2 m36.9 m45 m55.6 m

Operating expense total

51.4 m53.7 m57 m61.6 m56.3 m68 m68.6 m82.5 m89.3 m

EBIT

(55.1 m)(36.7 m)(28.1 m)(42 m)(26.2 m)(2 m)(15.3 m)(28.3 m)(39.7 m)

EBIT margin, %

(76%)

Interest expense

(5.3 m)(5.3 m)(5.2 m)(5.9 m)(10 m)(9.9 m)(9.8 m)(9.8 m)(9 m)

Net Income

(60.4 m)(42 m)(33.2 m)(48 m)(47.4 m)(13.3 m)(21.7 m)(33.2 m)(52.5 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

75.5 m74.3 m261.3 m54 m

Accounts Receivable

513 k10 k2.9 m933 k

Inventories

6.2 m10.6 m6.3 m1.1 m

Current Assets

229.1 m289.7 m500.2 m380.2 m

PP&E

37.4 m29.8 m21.1 m20.5 m

Goodwill

785 k

Total Assets

279 m333.5 m619.1 m709.8 m

Accounts Payable

10.1 m9.8 m8.6 m17.7 m

Total Debt

175.8 m6.2 m

Current Liabilities

41 m60.5 m76.5 m91.1 m

Common Stock

103 k125 k127 k133 k

Additional Paid-in Capital

815.9 m1.1 b1.2 b1.3 b

Retained Earnings

(777.8 m)(967.4 m)(1.1 b)(1.2 b)

Total Equity

38.2 m88.6 m95.1 m66.7 m

Debt to Equity Ratio

4.6 x0.1 x

Debt to Assets Ratio

0.6 x0 x

Financial Leverage

7.3 x3.8 x6.5 x10.6 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

95.4 m51.3 m63.7 m256.5 m248.1 m280.9 m277.3 m182.9 m133.3 m

Accounts Receivable

380 k862 k1.1 m2.6 m908 k1.3 m1.2 m1.2 m

Inventories

13 m13 m5 m1.5 m

Current Assets

325.8 m304.1 m263.9 m527 m505.8 m495.7 m386.1 m382.8 m357.9 m

PP&E

33.6 m30.4 m27.5 m25 m23.2 m19.4 m17.9 m18.8 m18.6 m

Goodwill

649 k649 k785 k

Total Assets

371.1 m346.2 m305.5 m653.9 m613.4 m603.3 m700.2 m732 m701.3 m

Accounts Payable

3.4 m6.1 m

Current Liabilities

41.6 m54.1 m59.8 m62.1 m67.8 m78.1 m91 m95.3 m78.9 m

Common Stock

120 k124 k126 k126 k127 k128 k130 k131 k134 k

Additional Paid-in Capital

1 b1 b1.1 b1.2 b1.2 b1.2 b1.2 b1.2 b1.3 b

Retained Earnings

(887.8 m)(929.8 m)(1 b)(1 b)(1.1 b)(1.1 b)(1.1 b)(1.2 b)(1.2 b)

Total Equity

141.8 m108.2 m68.2 m140.3 m100.5 m90.9 m81.4 m59.5 m29.6 m

Financial Leverage

2.6 x3.2 x4.5 x4.7 x6.1 x6.6 x8.6 x12.3 x23.7 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(272.8 m)(189.6 m)(142.7 m)(81.7 m)

Depreciation and Amortization

11.7 m12.3 m11.6 m10.3 m

Accounts Receivable

(1.7 m)(24 m)(29 m)(10.3 m)

Inventories

(52 k)(3.9 m)2.6 m(3.1 m)

Accounts Payable

(11.7 m)1.4 m

Cash From Operating Activities

(273.4 m)(155.6 m)(106.9 m)(25.4 m)

Purchases of PP&E

(9.6 m)(3.5 m)(4 m)(4.2 m)

Cash From Investing Activities

(101.4 m)(56.6 m)

Cash From Financing Activities

313.6 m210.9 m303.1 m(4.2 m)

Interest Paid

18.4 m19.6 m22.7 m24.5 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(60.4 m)(42 m)(33.2 m)(48 m)(47.4 m)(13.3 m)(21.7 m)(33.2 m)(52.5 m)

Accounts Receivable

380 k862 k1.1 m2.6 m908 k1.3 m1.2 m1.2 m

Inventories

13 m13 m5 m1.5 m

Accounts Payable

3.4 m6.1 m
USDY, 2017

Revenue/Employee

77.4 k

Financial Leverage

23.7 x

Ironwood Pharmaceuticals Market Value History

Ironwood Pharmaceuticals Median Salaries

Source: 16 public H-1B filings from Ironwood Pharmaceuticals

Traffic Overview of Ironwood Pharmaceuticals

Ironwood Pharmaceuticals Online and Social Media Presence

Ironwood Pharmaceuticals Company Life and Culture

You may also be interested in